The State of the Art on Blood MicroRNAs in Pancreatic Ductal Adenocarcinoma.
Zhuqing GaoShu-Tian ZhangShu Tian ZhangPeng LiPublished in: Analytical cellular pathology (Amsterdam) (2019)
Despite enormous advances being made in diagnosis and therapeutic interventions, pancreatic ductal adenocarcinoma (PDAC) is still recognized as one of the most lethal malignancies. Early diagnosis and timely curative surgery can markedly improve the prognosis; hence, there is an unmet necessity to explore efficient biomarkers for patients' benefit. Recently, blood miRNAs (miRNAs) have been reported to be a novel biomarker in human cancers. Part of it is selectively packaged by plasma exosomes released from cells via exocytosis and is highly sensitive to changes in the tumor microenvironment. Furthermore, due to less invasiveness and technical availability, miRNA-based liquid biopsy holds promise for further wide usage. Therefore, this review is aimed at presenting an update on the association between blood miRNAs and the biology of PDAC, then discussing its clinical utilization further.
Keyphrases
- end stage renal disease
- endothelial cells
- prognostic factors
- ejection fraction
- induced apoptosis
- minimally invasive
- chronic kidney disease
- peritoneal dialysis
- stem cells
- physical activity
- mesenchymal stem cells
- cell cycle arrest
- oxidative stress
- coronary artery bypass
- big data
- ionic liquid
- case report
- patient reported outcomes
- signaling pathway
- cell death
- coronary artery disease
- bone marrow
- molecularly imprinted
- percutaneous coronary intervention
- artificial intelligence
- patient reported
- pluripotent stem cells